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Abstract
Background: The lymphatics form a second circulatory system that drains the extracellular fluid
and proteins from the tumor microenvironment, and provides an exclusive environment in which
immune cells interact and respond to foreign antigen. Both cancer and inflammation are known to
induce lymphangiogenesis. However, little is known about bladder lymphatic vessels and their
involvement in cancer formation and progression.
Methods: A double transgenic mouse model was generated by crossing a bladder cancer-induced
transgenic, in which SV40 large T antigen was under the control of uroplakin II promoter, with
another transgenic mouse harboring a lacZ  reporter gene under the control of an NF-κB-
responsive promoter (κB-lacZ) exhibiting constitutive activity of β-galactosidase in lymphatic
endothelial cells. In this new mouse model (SV40-lacZ), we examined the lymphatic vessel density
(LVD) and function (LVF) during bladder cancer progression. LVD was performed in bladder whole
mounts and cross-sections by fluorescent immunohistochemistry (IHC) using LYVE-1 antibody.
LVF was assessed by real-time in vivo imaging techniques using a contrast agent (biotin-BSA-Gd-
DTPA-Cy5.5; Gd-Cy5.5) suitable for both magnetic resonance imaging (MRI) and near infrared
fluorescence (NIRF). In addition, IHC of Cy5.5 was used for time-course analysis of co-localization
of Gd-Cy5.5 with LYVE-1-positive lymphatics and CD31-positive blood vessels.
Results: SV40-lacZ mice develop bladder cancer and permitted visualization of lymphatics. A
significant increase in LVD was found concomitantly with bladder cancer progression. Double
labeling of the bladder cross-sections with LYVE-1 and Ki-67 antibodies indicated cancer-induced
lymphangiogenesis. MRI detected mouse bladder cancer, as early as 4 months, and permitted to
follow tumor sizes during cancer progression. Using Gd-Cy5.5 as a contrast agent for MRI-guided
lymphangiography, we determined a possible reduction of lymphatic flow within the tumoral area.
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In addition, NIRF studies of Gd-Cy5.5 confirmed its temporal distribution between CD31-positive
blood vessels and LYVE-1 positive lymphatic vessels.
Conclusion:  SV40-lacZ  mice permit the visualization of lymphatics during bladder cancer
progression. Gd-Cy5.5, as a double contrast agent for NIRF and MRI, permits to quantify delivery,
transport rates, and volumes of macromolecular fluid flow through the interstitial-lymphatic
continuum. Our results open the path for the study of lymphatic activity in vivo and in real time, and
support the role of lymphangiogenesis during bladder cancer progression.
Background
De novo lymphangiogenesis influences different patholog-
ical courses via modulating tissue fluid homeostasis, mac-
romolecule absorption, and leukocyte transmigration [1].
In addition, lymphatic vessels play a crucial role in a vari-
ety of human cancers [2]. Invasion of lymphatic vessels by
tumor cells and subsequent development of lymph node
metastases significantly influences the prognosis of cancer
patients and, therefore, represents an integral part of
tumor staging. Increasing knowledge of the tumor's bio-
logical significance in lymphatics within the tumors and
at the tumor periphery has greatly promoted understand-
ing of tumor access into the lymphatic system by inducing
lymphangiogenesis or by co-opting preexisting lymphat-
ics [2]. In contrast, impaired functioning of lymphatic ves-
sels results in lymphedema as observed during breast
cancer diagnosis and treatment [3-5].
During cancer progression, a bi-directional communica-
tion is established between the tumor microenvironment
(TME) and lymphatic vessels. In one direction, the lym-
phatic vasculature alters TME by draining the interstitial
protein-rich exudate fluid (lymph) into the bloodstream.
In another direction, inflammation influences the com-
position and pressure of TME leading to altered lymphatic
vessel function.
We choose to study bladder cancer because it represents
2% of all human malignancies. Urothelial carcinoma is
one of the most common cancers – it ranks fifth among all
cancers in the Western world, and there are 336,000 new
cases and 132,000 deaths annually worldwide [6]. In the
US alone, the American Cancer Society estimates that
50,040 men and 17,120 women will be diagnosed, and
13,060 men and women will die of cancer of the urinary
bladder in 2007 [7]. Although the role of lymphatic ves-
sels during bladder cancer progression is remarkably
unknown, invasion of lymphatics during bladder cancer
has been reported [8], whereas in prostate cancer there is
a decrease in intratumoral lymphatic vessel density [9].
More recently, Fernandez and collaborators published the
first manuscript suggesting the existence of proliferating
lymph vessels and, therefore, of lymphangiogenesis in
bladder transitional cell carcinoma (TCC), and proposed
strong correlation of higher peritumoral LVD with the
presence of lymph nodes in clinically localized invasive
bladder TCC [10]. However, up to now, no animal model
was available for a systematic study of lymphatic vessel
density and function during bladder cancer progression.
We previously described that a transgenic mouse (κB-
lacZ) with a reporter gene (lacZ) for NF-κB presented con-
stitutive β-galactosidase (β-gal) activity in all lymphatic
endothelial cells [11] and that these mice serve a dual pur-
pose by permitting both visualization of lymphatics and
detection of constitutive and inducible NF-κB activity
[11]. To study in-depth the role of lymphatic vessels in
bladder cancer progression, we generated a double trans-
genic mouse (SV40-lacZ) by crossing the κB-lacZ  mice
with a well established model of bladder cancer (UPKII/
SV40T) [12,13]. Here, we demonstrate that these SV40-
lacZ mice present an increased lymphatic vessel density
during bladder cancer progression.
We also show that a new compound, coined Gd-Cy5.5,
which corresponds to a recently described contrast agent
(biotin-BSA-Gd-DTPA) [14-16] conjugated to Cy5.5 per-
mits dual imaging by near-infrared fluorescent (NIRF)
and MRI. We, therefore, provide proof-of-concept that
this contrast agent can be used for determination of lym-
phatic vessel function during bladder cancer progression.
Methods
Animals
All experiments were performed according to the "Princi-
ples for Research Involving Animals and Human Beings
Guidelines" (OUHSC Animal Care & Use Committee pro-
tocol # 04–028). Double transgenic mice were obtained
by crossing κB-lacZ with UPKII/SV40T mice. The κB-lacZ
transgenic model used in this study was first described in
1996 [17] and enriched in the C57Bl/6 background. It was
constructed using the promoter of the gene encoding
p105, a precursor of the p50 subunit of NF-κB. This pro-
moter contains three NF-κB binding sites in its proximal
part driving the expression of lacZ with a nuclear localiza-
tion sequence. These mice permit the visualization of lym-
phatic endothelial cells in the urinary bladder and all
other tissues examined so far [17].BMC Cancer 2007, 7:219 http://www.biomedcentral.com/1471-2407/7/219
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A double transgenic mouse model (SV40-lacZ) was gener-
ated by crossing the κB-lacZ  transgenics with UPKII/
SV40T mice. UPKII/SV40T mice present the SV40 large T
antigen under the control of a urothelium-specific mouse
uroplakin II promoter, and develop specifically bladder
cancer [12,18,19]. The phenotype of each mouse was con-
firmed by southern blot analysis of SV40T and PCR for β-
galactosidase in tail vein snips. Only double positive mice
were used in these experiments. FVB mice were purchased
from Jackson Labs, crossed with κB-lacZ, and used as con-
trols for UPKII/SV40T mice.
Lymphatic Vessel Density (LVD)
We follow the "Reporting Recommendations for tumor
Marker (REMARK)" guidelines [20]. This consensus report
aims to lower the methodological variability of lym-
phangiogenesis quantification in tissue sections. The rec-
ommendations include: 1) double-blinded experiments;
2) the use of multiple IHC stains on serial sections (We
used LYVE-1 IHC that has been established in our labora-
tories [11] and X-gal staining for β-galactosidase, because
the SV40-lacZ enable this stain for visualization of lym-
phatic vessels [11]); and 3) the use of a double immunos-
taining of lymphatic marker and those for cell
proliferation. In this context, bladder cross-sections were
double stained with LYVE-1 and Ki-67 antibodies.
LVD in bladder whole-mounts
LVD was determined as described before [11,17]. Eight
mice per point were euthanized with sodium pentobarbi-
tal (100 mg/kg, i.p.) and tissues were removed rapidly and
stained as whole mounts with X-gal. β-galactosidase activ-
ity was revealed by X-gal staining at 30°C for 4–6 hours.
Whole mounts were examined under a dissecting scope
(SMZ 1500, Nikon). All tissues were photographed by a
digital camera (DXM1200; Nikon). Exposure times were
held constant when acquiring images from different tis-
sues. Afterwards, tissues were washed four times in PBS
and post-fixed in 2% paraformaldehyde in PIPES [pipera-
zine diethanesulfonic acid]. Lymphatic vessel density was
quantified by morphometric analysis using Neurolucida
workstation (MicroBrightField, Inc) [21], as described (ref
[11]; supplemental material). Morphometric analysis was
performed by importing Neurolucida tracings into Neu-
roExplorer software version 3.70.2 (MicroBrightField,
Inc) [21]. The ratio between the area occupied by lym-
phatics and the total tissue area (μm2) was then deter-
mined for each section and statistical analysis was
performed using a Wilcoxon's rank sum test. Results are
expressed as mean ± SEM. In all cases, a value of p < 0.05
was considered indicative of a significant difference [22].
This method may result in the overestimation of the lym-
phatic area. The software uses the 3D surface area of lym-
phatics, estimated from a 2D projection. Also, tissue area
was calculated from a 2D projected cross-sectional tissue
area (tissue contour).
Fluorescence IHC
Frozen bladders were processed for routine IHC according
to published methods [23]. Frozen sections were post-
fixed in 1% formaldehyde. All reagent incubations and
washes were performed at room temperature. 5% normal
donkey blocking serum (Jackson Immunolabs) was
placed on all slides for 45 min and sections were incu-
bated with primary antibody for 1 hour and 45 minutes in
a humidifier chamber. Slides were washed 3× 5 minutes
in PBS and incubated with secondary antibodies. Slides
were washed, counterstained with DAPI [4',6-diamidino-
2-phenylindole; 1:20,000 dilutions of 10 mg/ml] for 2
minutes and coverslipped with Shur/Mount (TBS)
mounting media and sealed with nail polish. All tissue
cross-sections were visualized with a Nikon Eclipse TE
2000-S inverted fluorescent microscope (Nikon) [24] and
imaged at room temperature using a digital CCD camera
(Roper Scientific) [25], driven by NIS-Elements AR2.3
Imaging software (Laboratory Imaging/Nikon) [26]. Con-
trols included omission of the primary antibody. Anti-
bodies used in this work are listed in Table 1. All
secondary antibodies were used at a 1:400 dilution. Sec-
ondary antibodies included donkey anti-rabbit IgG AF488
conjugate (Molecular Probes; probes.invitrogen.com),
donkey anti-goat IgG (Alexa Fluor 546, A11056, Invitro-
gen), and donkey anti-rat IgG (AlexaFluore 488).
LVD and image analysis of bladder cross-sections
At least 6 random fields per cross-section were visualized
at 20× magnification and used for image analysis that was
performed with the NIS-Elements Advanced Research 2.3
imaging software [26]. This software identifies signal by
thresholding key intensity values. Further the software
permits imposing restrictions to the measurements by
excluding false positive signals. Briefly, the number of
Table 1: Primary antibody characteristics
Antigen Host Species Against Dilution Code Supplier
CD31 Rat Mouse 1:50 550274 Abcam [67]
LYVE-1 Rabbit Mouse 1:400 ab14917 Abcam [67]
Ki-67 Goat Mouse 1:500 sc-7846 Santa Cruz [68]
MAC 387 (calprotein Ab-1) monoclonal Mouse Mouse 1:1000 Mac 387 Lab Vision [69]BMC Cancer 2007, 7:219 http://www.biomedcentral.com/1471-2407/7/219
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positive cells expressing a particular antibody was calcu-
lated as percent of the region of interest (ROI), as indi-
cated in the individual figure legend. Co-localization of
two antibodies was calculated by converting the area
occupied by cells positive for the first antibody into a ROI.
Then the percent of cells that were positive for the second
antibody was calculated within the ROI. Results are
expressed as mean ± SEM. In all cases, a value of p < 0.05
was considered indicative of a significant difference [22].
NIRF
Mice were fed a low-chlorophyll diet for 2 weeks to reduce
auto-fluorescence in the intestinal region [27] and the
abdominal hair was removed. Mice were anesthetized
with isoflurane, placed in a heating pad, and received 200
μL of the Gd-Cy5.5 intravenously, and the accumulation
of Cy5.5 into the urinary bladder was followed over time.
Anesthetized mice were immediately placed on a heating
pad inside a FluorChem HD2 (Alpha Innotech, San Lean-
dro, CA) equipped with a Chromalight® multi-wavelength
illuminator and a 4-million pixel Cooled camera (F2.8
manual zoon lens and F1.4 fixed lens) coupled to a dedi-
cated computer. The FluorChem cabinet permits contin-
ued anesthesia with isoflurane. Images were first acquired
and stored with AlphaEase FC® 32-bit software (Alpha
Innotech, San Leandro, CA) and subsequently, applica-
tion of black-and-white and color gradients were per-
formed in Adobe Photoshop® CS3 extended [28] that
permitted the determination of integrated density. For
this purpose, an elliptical marquee of fixed size (180 ×
180 px) was used to determine the region of interest (ROI)
around the luminescence zones corresponding to a blad-
der area and the count tool was used to determine and
record each integrated density. The integrated density cor-
responded to the sum of the values of the pixels in the
ROI, which were equivalent to the product of the area (in
pixels) and mean gray value.
MRI
All data was acquired using a Bruker 7 Tesla/30 cm hori-
zontal bore magnet. Anatomical scans acquired proved to
be useful in elucidating normal and bladder tumor tissue.
Bladder and tumor physiology was followed in a time
course study using this method at each time point, for
each animal. This method is a dual spin-echo technique
modified from a MSME (Multi-Slice Multi-Echo) tech-
nique designed to yield anatomical T1 and T2 weighted
images for each slice position in the slice package. Axial
scans acquired had the following parameters: TR = 900
ms, TE = 11.6 ms, slice thickness = 0.75 mm, NA = 4, slice
gap = 0.05 mm, FOV = 2.5 cm × 2.5 cm, matrix size = 256
× 256, giving an in-plane resolution of 98 μm × 98 μm.
T1-weighted images had an effective TE of 17 ms, and T2-
weighted images had an effective TE of 52 ms. Acquired
parameter images had TE = 15 ms over a range of 5 TR
increments with values = (100, 300, 450, 600, 850, and
1150 ms), slice thickness = 0.75 mm (position of slice var-
ied according to tumor location), FOV = 2.5 cm × 2.5 cm,
NA = 2, matrix size = 128 × 128, and an in-plane resolu-
tion of 195 μm × 195 μm. Mono-exponential fits were uti-
lized to calculate actual T1 values in post-processing.
Synthesis of biotin-BSA-GdDTPA compound
The macromolecular contrast material, biotin-BSA-
GdDTPA, was prepared by the modification of the
method of Dafni and collaborators [29]. Bovine serum
albumin (BSA, 0.5 g, 8 μmol; Sigma) was dissolved in 0.1
M sodium bicarbonate (7.5 ml, pH 8.5). Sulfo-NHS-
Biotin (22.4 mg; 53 μmol; Pierce) was dissolved in double
distilled water (DDW, 1.2 ml) and was added to BSA
while stirring. The reaction mixture was stirred for 1 hr at
4°C and an additional 2 hrs at room temperature. The
dialyzed product in 0.1 M Hepes buffer (pH 8.8) was
reacted with diethylene triamine pentaacetic acid anhy-
dride (DTPA, 0.5 g, 1.4 mmol; Sigma) suspended in 2.5
ml of dimethyl sulfoxide (DMSO) at room temperature.
DTPA was added in portions and the pH was adjusted
immediately after each addition to 8.5 with 5 N NaOH.
The reaction mixture was stirred for 2 hrs at 4°C and
extensively dialyzed against cold 0.1 M citrate buffer (pH
6.5). Finally, gadolinium (III) chloride (GdCl3, 0.25 g;
0.67 mmol; Sigma) in 2.5 ml 0.1 M sodium acetate buffer
(pH 6.0) was added gradually, and the mixture was stirred
for 24 hrs at 4°C. The product, biotin-BSA-GdDTPA, was
extensively dialyzed against cold citrate buffer (0.1 M, pH
6.5) and then against DDW. The product was lyophilized
and stored at 4°C. For Cy5.5 -Gd preparation, 10 mg of
dry lyophilized product (biotin-BSA-GdDTPA) was recon-
stituted in 150 μl of sodium bicarbonate buffer 0.1 M pH
8.8 NaHCO3. Cy5.5 dye (Cy5.5 mono functional reactive
dye, Amersham Biosciences) was dissolved in 10–20 μl of
DMF and added to the product. The mixture was incu-
bated in the dark at RT for 1 hr while mixing. The final
compound biotin-BSA-GdDTPA-Cy5.5 was purified using
Zeba 2 ml columns and had a molecular weight of ~82
kDa.
Other compounds
Dextran (500,000 MW)-Cy5.5 (Dex 0003–5) was pur-
chased from Nanocs [30].
Results
Visualization of bladder lymphatics
As the parent mouse model (κB-lacZ) permitted the visu-
alization of lymphatic vessels by the expression of β-galac-
tosidase, we investigated whether the double transgenic
maintained this capacity. Figure 1A is a representative
whole mount X-gal staining of bladders isolated from
SV40-lacZ indicating that these mice maintained the con-
stitutive activity of NF-κB in lymphatic vessels. Positive X-BMC Cancer 2007, 7:219 http://www.biomedcentral.com/1471-2407/7/219
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gal staining was also observed in cross sections left
unstained (Figure 1B) or counter stained with H&E (Fig-
ure 1C and 1D). High magnification pictures of bladder
cross sections indicate a nuclear localization of β-galactos-
idase expression in lymphatic endothelial cells due to a
nuclear localization sequence of the original construct of
the transgenic mouse (Figure 1D). Double staining of
whole mounts confirmed that all β-galactosidase positive
vessels were also LYVE-1-positive, and therefore, were
lymphatic vessels (Figure 1E). In addition to lymphatic
endothelial cells, cells morphologically resembling mac-
rophages were the only other cell type that also showed
LYVE-1 staining (Figures 2 A–C). This was further sup-
ported by the fact that these macrophage-like cells
expressed MAC3, a macrophage marker [31] (Figures
2D–F). In contrast, other inflammatory cells were nega-
tive for LYVE-1 IHC. This is the case of mast cells present
in the mouse bladder (Figure 2G–H).
Increased lymphatic vessel density (LVD) during mouse BC 
progression
Lymphatic vessel density was determined in control (FVB-
κB-lacZ) and SV40-lacZ  mice by Neurolucida®  guided
morphological analysis of LYVE-1 IHC stained bladder
whole mounts, as described (supplemental material to
manuscript [11]) and in cross-sections by fluorescent
IHC. Figure 3A and 3B are representative LYVE-1 IHC of a
urinary bladder isolated from SV40-lacZ  mice. LYVE-1
staining was correlated with β-gal expression leading to
results similar to those presented in Figure 1E and, there-
fore, indicating that the vessels represented in Figure 3A
are indeed lymphatics. After IHC with LYVE-1 (Figure 3A)
Neurolucida® was used to trace and quantify the region of
interest (ROI = white dotted line) and volume of lym-
phatic vessels (Figure 3B). Figure 3C presents the lym-
phatic vessel density (percent per unit of area) indicating
that compared to 6-months old FVB-κB-lacZ mouse (n =
12), SV40-lacZ mice (n = 4 for each time point) presented
a significant increase in LVD in the adventitia during can-
cer progression (BC = mean LVD 39.3% (n = 20); and con-
trol (FVB-κB-lacZ mice) = mean LVD 24.3%, [n = 12]; p <
A-E. Visualization of lymphatic vessels in a double transgenic mouse model Figure 1
A-E. Visualization of lymphatic vessels in a double transgenic mouse model. SV40-lacZ mice obtained by crossing κB-lacZ mice 
with UPKII/SV40 maintain the capacity of the parent mice in developing bladder carcinoma in situ (CIS) and labeling of bladder lymphatic 
vessels. A represents X-Gal staining of bladder whole mounts isolated from SV40-lacZ mice, indicating a rich network of lymphatic ves-
sels in the bladder adventitia. Cross-sections of the urinary bladder illustrated in A were left unstained (B) or counter stained with H&E 
(C-D). Figure C is a representative of bladder adventitia and D is a high magnification of lymphatic vessels present in the detrusor 
smooth muscle. Arrows (B, C, and D) indicate the presence of β-galactosidase-positive lymphatic endothelial cells. E is a representative 
whole mount of bladders isolated from SV40-lacZ mice subsequently stained with X-gal to reveal β-galactosidase-positive cells (blue) and 
LYVE-1 IHC to reveal lymphatic endothelial cells (brown). Note the complete overlap of labels confirming constitutive NF-κB activity in 
lymphatic vessels.
X7.5
A
DOME
NECK
X400
E
Adventitia Detrusor
X100 B
X200
C
D
X1000BMC Cancer 2007, 7:219 http://www.biomedcentral.com/1471-2407/7/219
Page 6 of 20
(page number not for citation purposes)
0.001). This increase in LVD was observed in as young as
4-month old mice and remained elevated in all age groups
studied so far (up to 9 months). Because LVD in whole
mounts could only take into consideration medium and
large lymphatics, an additional group of mice had their
bladders removed and their cross-sections were studied by
fluorescent IHC using LYVE-1 antibody. Image analysis of
the cross-sections of 9-month old FVB-κB-lacZ and SV40-
lacZ mice (ages 7, 9, and 11 months) are presented in Fig-
ure 3D (a total of 11 control and 12 SV40-lacZ cross-sec-
tions were examined), confirming a significant increase in
LVD during bladder cancer progression.
Bladder cancer-induced lymphangiogenesis
Next, the same cross- sections used for quantification of
LYVE-1 were double labeled with LYVE-1 and an anti-goat
polyclonal antibody against Ki-67(M-19), a nuclear pro-
tein expressed in proliferating cells that may be required
for maintaining cell proliferation [32,33], and that pro-
vides the same value for proliferation index as BrdU in
urothelial cancer cells [33]. Figure 4A–D is a representa-
tive photomicrograph of sub-urothelial lymphatic vessels
illustrating the finding that some of the lymphatic
endothelial cells were positive for both LYVE-1 and Ki-67.
These results indicate the presence of cancer-induced lym-
phangiogenesis in this mouse model.
Lymphatic Vessel Function (LVF) by NIRF
For NIRF, a total of 9 SV40-lacZ mice ages 6–11 months
were used. Mice were fed a low-chlorophyll diet for 2
weeks to reduce auto-fluorescence in the intestinal region
[27] and the abdominal hair was removed. Mice were
anesthetized with isofluorane and received 200 μL Gd-
Cy5.5 intravenously (dose of 500 mg/kg), and the accu-
mulation of Cy5.5 into the urinary bladder was followed
over time.
A time-course of Cy5.5 accumulation in the lower abdom-
inal region of SV40-lacZ is illustrated in Figures 5A–5F.
Additional mice, represented in Figures 5G–J, have their
abdomen opened and the gastrointestinal tract removed
to permit better visualization of the pelvic floor. Near
Presence of LYVE-1-positive macrophages during bladder cancer progression Figure 2
Presence of LYVE-1-positive macrophages during bladder cancer progression. Representative photomicrographs indicating 
LYVE-1-positive cells resembling macrophages (red arrows) in the urinary bladders obtained from SV40-lacZ mice. A = LYVE-1 and 
Giemsa stain. B and C = LYVE-1 and H&E stained cross-sections. D, E, and F = MAC 387 immunohistochemistry (blue arrows) per-
formed in serial sections of the same bladders represented in A, B, and C. Mast cells (black arrows) present in the cross-sections were 
positive for Giemsa stain, but negative for LYVE-1 (D and E).
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infra red fluorescence of the regions within red circles on
Figures 5A–F is represented as integrated density in Figure
5K. The numbers in each segment indicate the time lapse
after i.v. administration of Gd-Cy5.5. An absence of spe-
cific fluorescence in the lower abdominal regions of mice
at zero and 10 min after Gd-Cy5.5 administration (Figure
5A and 5B) is observed. A gradual accumulation of Cy5.5
was observed and a fluorescence peak occurred in the
bladder region at 120 minutes (Figure 5B and 5F). At 240
minutes a significant amount of fluorescence still
Bladder cancer-induced lymphangiogenesis Figure 4
Bladder cancer-induced lymphangiogenesis. Next, the same cross- sections illustrated in Figure 3 were double-labeled with anti-
bodies against LYVE-1 and a marker of cell proliferation, Ki-67. A-D are representative photomicrographs of the sub-urothelial lymphatic 
vessels illustrating the finding that some of the lymphatic endothelial cells were positive for both LYVE-1 (green fluorescence in B) and 
cell proliferation (Ki-67-positive cells are in red fluorescence in C), as illustrated by a yellow labeling of merged images in D. These results 
indicate the presence of cancer-induced lymphangiogenesis in this mouse model. Blue stain in A is DAPI (4',6-diamidino-2-phenylindole) 
which highlights the cell nuclei.
100 px
A B C D
DAPI LYVE-1 Ki-67 MERGE
A-D.Increased lymphatic vessel density during bladder cancer progression Figure 3
A-D. Increased lymphatic vessel density during bladder cancer progression. LYVE-1 IHC quantification of lymphatic vessel den-
sity (LVD) in bladders isolated from control and SV40-lacZ mice. A = Representative photomicrographs of LYVE-1 IHC. B = Neurolucida 
tracing of lymphatics. C = Lymphatic vessel density during cancer progression in whole mount preparations of LYVE-1 stained bladders 
isolated from SV40-lacZ mice compared to control (FVB-κB-lacZ = pink). D = Lymphatic vessel density during cancer progression in 
cross-section preparations of LYVE-1 stained bladders isolated from SV40-lacZmice compared to control (FVB-κB-lacZ = pink). Asterisks 
indicate a statistical significant difference (p < 0.05) between FVB-C57BL/6 and SV40-lacZ mice.
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remained in the urinary bladder (Figure 5C and 5G). At
330 minutes the urinary bladders revealed low NIRF (Fig-
ure 5E and 5I) when compared to the fluorescence peak
observed at 120 minutes, and at 24 hours (1440 min)
only residual fluorescence was observed (Figure 5J). In
addition, it should be noted that emptying the residual
urinary content of the bladder did not alter significantly
the intensity of fluorescence, indicating that the residual
fluorescence corresponded to Cy5.5 which still remained
within the bladder parenchyma. Outside the urinary blad-
der, Cy5.5 accumulated in the kidneys (green arrows) and
in lymph sacs (blue arrows in Figures 5G, 5I and 5J).
Co-localization of Cy5.5 with LYVE-1 positive lymphatics 
and CD31-positive blood vessels
To confirm the results obtained in vivo, groups of mice (n
= 3) were euthanized at 2, 5.5, and 24 hours (120, 330,
and 1440 minutes) after i.v. administration of Gd-Cy5.5
and the bladders were removed for analysis of co-localiza-
tion of Cy5.5 with LYVE-1- and CD31-positive cells. Fig-
ures 6, 7, 8 contain representative photomicrographics of
confocal analysis of bladder cross-sections and the results
of image analysis performed in all sections are presented
in Figure 9. In all figures, the red represents Cy5.5 accu-
mulation and the blue stain is DAPI (4',6-diamidino-2-
phenylindole), which highlights the cell nuclei. The yellow
label indicates co-localization of Cy5.5 with CD31-posi-
tive blood vessels, or LYVE-1-positive lymphatic vessels.
In particular Figures 6 A–B and 7 A–B indicate the sub-
urothelial localization of blood vessels whereas lymphatic
vessels are seen in the deeper regions of the mucosa but
not in the subepithelial layer. Figures 8 A–D indicate that,
at 1140 minutes, a significant amount of Cy5.5 still
remains in the bladder parenchyma which may explain
the fluorescence observed in Figure 5K.
Lymphatic Vessel Function (LVF) by NIRF Figure 5
Lymphatic Vessel Function (LVF) by NIRF. For NIRF, a total of 9 SV40-lacZ mice ages 6–11 months were used. Mice were fed a 
low-chlorophyll diet for 2 weeks to reduce auto-fluorescence in the intestinal region and the abdominal hair was removed. Mice were 
anesthetized with isofluorane and received 200 μL Gd-Cy5.5 intravenously (dose of 500 mg/kg), and the accumulation of Cy5.5 into the 
urinary bladder was followed over time (A – F). Additional mice, represented in G-J, have their abdomen opened and the gastrointestinal 
tract removed to permit better visualization of the pelvic floor. NIRF of the regions within red circles on A-F is represented as average ± 
SEM of the integrated density × 107 (K). The numbers in each segment indicate the time lapse after i.v. administration of Gd-Cy5.5. Out-
side the urinary bladder, Cy5.5 accumulated in the kidneys (green arrows) and in lymph sacs (blue arrows in G, I, and J).
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Image analysis indicates that at all time points the area of
the bladder cross-sections occupied by CD31-positive
blood vessels was greater than the area occupied by LYVE-
1-positive lymphatic vessels (Figure 9). In terms of co-
localization of Cy5.5, at 120 minutes, Cy5.5 was found
evenly distributed between LYVE-1-positive lymphatics
and CD31-positive blood vessels (Figure 9). At 330 min-
utes a great proportion of Cy5.5 was found within LYVE-
positive lymphatic vessels, and at 1140 minutes, most of
the Cy5.5 was found within lymphatic vessels (Figures 9).
These results provided the basis for subsequent MRI anal-
ysis of lymphatic vessel function.
NIRF visualization of abdominal large lymphatic vessel 
draining the urinary bladder
A constant feature observed following i.v. administration
of Cy5.5-conjugates was the labeling of abdominal lym-
phatic sacs (blue arrows in Figures 5G, 5I, and 5J). In
order to investigate whether NIRF would permit visualiza-
tion of these collecting lymphatic vessels and lymph sacs,
high molecular weight dextran (500,000 MW)-Cy5.5 was
injected in the pelvic floor underneath the urinary blad-
der, in the same region of lymph sacs of anesthetized mice
and serial images were immediately captured. Figures 10
A–D are negative NIRF images acquired along with time
and indicate the movement of Cy5.5 in major collecting
lymphatic vessels and Figures 10E and 10F are higher
magnifications of the same system. It was noted that a
series of lymph sacs were observed squirting the fluores-
Distribution of Cy5.5 between blood and lymphatic vessels at 120 minutes after administration of Gd-Cy5.5 Figure 6
Distribution of Cy5.5 between blood and lymphatic vessels at 120 minutes after administration of Gd-Cy5.5. To confirm 
the results obtained in vivo, groups of mice (n = 3) were euthanized at 120 minutes after i.v. administration of Gd-Cy5.5 and the bladders 
were removed, frozen, and prepared for confocal analysis of the co-localization of Cy5.5 with CD31-positive vessels (green fluorescence 
in A and C) or LYVE-1-positive lymphatic vessels (green fluorescence in B and D). A and B are representative microphotographs of the 
same sub-epithelial region, whereas C and D are representative photomicrographs of the detrusor smooth muscle. Note that blood ves-
sels are just underneath the urothelial cell layer (A), whereas lymphatic vessels are deeper in the submucosa (B). The white arrows in A 
indicate Cy5.5 (red) that is co-localized with LYVE-1-positive cells in B (yellow arrows). The cyan arrow in B indicates Cy5.5 (red) that is 
co-localized with CD31-positive blood vessels in A (orange arrows). In all figures, the red represents Cy5.5 accumulation and the blue 
stain is DAPI. The yellow fluorescence indicates co-localization of Cy5.5 with CD31-positive blood vessels (A) or LYVE-1-positive lym-
phatic vessels (B). Quantification of the fluorescent signals by image analysis is presented in Figure 9.
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cent content rhythmically and upwards (black and white
arrows indicate the direction of the flow in two major col-
lecting lymphatic vessels). A quick time movie (Addi-
tional File 1), illustrates the upward movement of Cy5.5
within collecting lymphatic vessels shown in Figure 11.
Two hours after dextran-Cy5.5, the abdomen was opened
and the gastrointestinal tract was removed, and represent-
ative photomicrographs were taken in black-and-white
(Figure 12A) or artificially-colored to provide a gradation
of fluorescence distribution (Figure 12B). It can be
noticed that Cy5.5 accumulation occurred primarily in
the bladder, uterus, and lymph sac or cysterna. NIRF also
permitted the guided capture of tissues or organs with
high fluorescence intensity. In this way, lymph sacs were
dissected under fluorescence and processed for histology.
Figure 12C is a composite of a cross-section of a lymph sac
showing an interesting pattern of concentric paths of
smooth muscle (black dotted circle) that can be appreci-
ated at higher magnification in Figure 12D. A region with
high concentration of lymphocytes was also visible (wavy
black line on Figure 12C) and at the confocal level, it was
possible to determine the presence of CD-31-positive
blood vessels (Figure 12E; green) and LYVE-1-positive
lymphatic vessels (Figure 12F; green) draining this region.
In both figures, the red represents Cy5.5 accumulation
and the blue stain is DAPI.
Although this work is very preliminary, it permitted our
laboratory to identify and measure lymphatic function in
vivo and in real time. These results indicate that NIRF can
be use to study how Cy5.5-conjugate compounds are dis-
tributed between the interstitial fluid, blood vessels, and
lymphatics. Figure 5K illustrates the kinetics of Gd-Cy5.5
and permitted the follow up of lymphatic vessel function
by MRI (see below). In addition, large collecting lymphat-
ics can be identified, the propulsion of lymph within lym-
phatic vessels can be visualized, and movies can be used
Distribution of Cy5.5 between blood and lymphatic vessels at 330 minutes after administration of Gd-Cy5.5 Figure 7
Distribution of Cy5.5 between blood and lymphatic vessels at 330 minutes after administration of Gd-Cy5.5. Photomicro-
graphs obtained 330 minutes after i.v. administration of Gd-Cy5.5. A and B are representatives of the urothelial region whereas C and D 
are representatives of the adventitial region. Arrow's color scheme, as described in Figure 6. Quantification of the fluorescent signals by 
image analysis is presented in Figure 9.
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to study these dynamics (Figure 11). Finally, NIRF-guided
capture permitted us to start observing collecting lym-
phatics and lymph sacs and, therefore, to further study
their structures.
Magnetic Resonance Imaging of mouse urinary bladder 
cancer
Thanks to a unique rodent-dedicated MRI facility on cam-
pus [34], we were able to meet two major goals regarding
the SV40-lacZ mice. The first goal was to detect the pres-
ence of BC as early as possible. This permitted a longitudi-
nal study of tumor sizes during cancer progression. The
second goal was to determine whether the observed
increase in LVD was accompanied by an increased lym-
phatic function. A total of 7 SV40-lacZ mice and 3 wild
type controls (FVB crossed with κB-lacZ mice) entered the
study. Out of the 7 SV40-lacZ mice, 5 developed bladder
tumors and 1 had to be euthanized.
We were successful in early bladder cancer detection, and
MRI technology permitted the detection of bladder cancer
as early as in 6 months (youngest animal scanned). Fig-
ures 13, 14, and 15 are representative double echo MRIs
of 6-month old SV40-lacZ mouse bladder. Additional file
2 is a movie obtained during pre-contrast MRI indicating
the different scanning positions (Figure 13). Additional
file 3 is a post-contrast (Gd-Cy5.5) MRI movie that is
highlighted in Figure 14. Figure 15 is a detail of the last
frame of movie presented in additional file 3 (a red circle
delimits the urinary bladder and waved green line delim-
its tumor areas that are darker than the normal tissue).
Overall, the urinary bladders averaged volumes of 219.2 ±
74 mm3. In contrast, the total area of the tumors averaged
0.31 ± 0.1 cm2, occupying areas of 31 ± 12.7 mm2 and vol-
umes of 15.6 ± 6 mm3. The smallest bladder tumor
detected by MRI had a volume of 2.1 mm3. The tumor
fractional volume in comparison with the whole bladder
averaged 0.11 ± 0.02%. Longitudinal studies indicated
Distribution of Cy5.5 between blood and lymphatic vessels at 1440 minutes after administration of Gd-Cy5.5 Figure 8
Distribution of Cy5.5 between blood and lymphatic vessels at 1440 minutes after administration of Gd-Cy5.5. Photomi-
crographs obtained 1440 minutes after i.v. administration of Gd-Cy5.5. A and B are representatives of the urothelial region, whereas C 
and D are representatives of the adventitial region. Arrow's color scheme, as described in Figure 6. Quantification of the fluorescent sig-
nals by image analysis is presented in Figure 9.
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that in some mice the tumor tripled its initial volume over
2 months (Figure 16).
Dynamic contrast-enhanced MRI and Gd-Cy5.5 for 
determination of LVF
Dynamic contrast-enhanced MRI (DCE-MRI) images with
the use of the contrast agent Gd-Cy5.5 were acquired sub-
sequent to anatomical scans providing sensitive regions of
interest (ROI) for calculating T1 values between normal
and bladder tumor relaxation times. We found an
increased signal (due to decreased T1 relaxation) that cor-
related with an increased uptake of the Gd-probe from the
blood vessels into the urinary bladder extra vascular
space. The bladder volume did not change significantly
during the imaging period. However, there may have been
some motion artifacts associated with respiratory motion
that was not compensated with respiratory gating. Figure
17A is a gray scale representation of peak accumulation of
the Gd-probe in the bladder wall, except within tiny
regions (a red circle delimits the urinary bladder and
green lines indicated two tumor areas that are darker than
the normal tissue). Figure 17B represents the difference
image obtained at 30 minutes post-Gd-probe contrast
subtracted from the pre-contrast image. This image illus-
trates an early enhancement by the contrast agent into the
urinary bladder extravascular space, which may be attrib-
uted to vascular leakage. Figure 17C represents difference
image obtained at 80 minutes post-contrast subtracted
Image Analysis of bladder cross-sections obtained at 120,  330, and 1440 minutes (n = 3 mice per time point) Figure 9
Image Analysis of bladder cross-sections obtained at 120, 330, and 
1440 minutes (n = 3 mice per time point). Six random fields per 
cross-section were visualized at 20× magnification and used for 
image analysis that was performed with the NIS-Elements 
Advanced Research 2.3 imaging software (see Methods). Results 
are presented as mean and SEM. Asterisks indicate a statistically 
significant difference (p < 0.05) between the bladder area covered 
by blood vessels (CD-31) and lymphatic vessels (LYVE-1), whereas 
a pound sign indicates a statistically significant difference (p < 0.05) 
between the distribution of Cy5.5 in CD-31-positive blood vessels 
and LYVE-1-positive lymphatic vessels.
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NIRF visualization of abdominal large lymphatic vessel draining the urinary bladder Figure 10
NIRF visualization of abdominal large lymphatic vessel draining the urinary bladder. A constant feature observed following 
i.v. administration of Cy5.5-conjugates was the labeling of abdominal lymphatic sacs (blue arrows in Figures 5G, 5I, and 5J). In order to 
investigate whether NIRF would permit visualization of these collecting lymphatic vessels and lymph sacs, high molecular weight dextran 
(500,000 MW)-Cy5.5 was injected in the pelvic floor underneath the urinary bladder, in the same region of lymph sacs of anesthetized 
mice, and serial images were immediately captured. Figures 10 A-D are negative NIRF images acquired along with time and indicate the 
movement of Cy5.5 in major collecting lymphatic vessels. It was noted that a series of lymph sacs were observed squirting the fluorescent 
content rhythmically and upwards (black and white arrows indicate the direction of the flow in two major collecting lymphatic vessels). A 
quick time movie, Figure 10 E illustrates the upward movement of Cy5.5 within collecting lymphatic vessels. Figures 10 F and 10 G are 
a high magnification of an individual frame of the movie illustrated in Figure 11 and additional file 1.
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A B C DBMC Cancer 2007, 7:219 http://www.biomedcentral.com/1471-2407/7/219
Page 13 of 20
(page number not for citation purposes)
from 30 minutes post-contrast. This image demonstrates
a delayed enhancement due to drainage and pooling of
the contrast agent, which may reflect uptake within the
lymphatics in the bladder. Figure 17D represents the dif-
ference image obtained between images in 17B and 17C
(80 min. post-contrast minus 30 min post-contrast, and
the 30 min. post-contrast minus the pre-contrast images).
This image suggests that there is decreased drainage
within tumorigenic areas and perhaps a pronounced
increase in uptake in the lymphatics within normal
regions.
Because drainage of macromolecules by the lymphatics is
a slow event with rates of 2.3 to 3.7 μl/g minutes, images
were acquired in two "phases" corresponding to the
biphasic kinetics of the BSA-Gd-DTPA [15]. The first or
"early phase" is comprised of images obtained just before
i.v. administration of 200 μL Gd-Cy5.5 (dose of 500 mg/
kg). Starting at 3 minutes post-injection, images were
acquired every 7 minutes, up to 2 hours post-contrast. The
second block of MRI data was acquired up to 80 minutes
after the first series of images. A digital subtraction of the
images between pre- and 80 minutes post-contrast follow-
Isolated frame of a movie (additional file 1) presenting the  visualization of high molecular weight dextran (500,000  MW)-Cy5 Figure 11
Isolated frame of a movie (additional file 1) presenting the visuali-
zation of high molecular weight dextran (500,000 MW)-Cy5.5 by 
NIRF.
NIRF-guided capture of lymph sacs Figure 12
NIRF-guided capture of lymph sacs. Dextran-500,000 MW-Cy5.5 was administered in the pelvic floor underneath the urinary blad-
der. Two hours after dextran-Cy5.5, the abdomen was opened and the gastrointestinal tract was removed, and representative photomi-
crographs were taken in black-and-white (A) or artificially-colored to provide a gradation of fluorescence distribution (B). Fluorescent 
lymph sacs (white circle in A and B) were captured and dissected under fluorescence, and subsequently frozen for histology. C is a com-
posite of an H&E stained cross-section (originally at ×100) of a lymph sac showing an interesting pattern of concentric paths of smooth 
muscle (dotted black circle) that can be appreciated at higher magnification in D. A region with high concentration of lymphocytes was 
also visible (wavy black line in figure C). This region was processed for fluorescent Immunohistochemistry and at the confocal level, it was 
possible to determine the presence of CD-31-positive blood vessels (E; green) and LYVE-1-positive lymphatic vessels (F; green) draining 
this region. In figures E and F, the red represents Cy5.5 accumulation and the blue stain is DAPI. Original magnifications were: C = ×100, 
D = ×400, E = ×400, and F = ×400.
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ing Gd-Cy5.5 in three contiguous slices from the same
bladder (positions -0.2, -0.8, and +0.8) was artificially
colored (Figures 18A, 18B, and 18C). The red and yellow
regions are active lymphatic vessels and consist of drain-
age events within the bladder interstitium. Figure 19 rep-
resents the comparison between tumor-bearing bladders
(Figure 19A) and controls (Figure 19B and 19C). T1 val-
ues from these regions were normalized as percent of the
reference site (muscle). This figure represents the time-
dependent clearance of the contrast agent away from the
bladder and provides a strong indication of LVF. Note the
difference in T1 values between a tumor region and an
adjacent normal bladder region (Figure 19A). In control
bladders, two different normal regions were compared.
These results suggested decreased drainage in the areas
bearing tumors in comparison to normal areas.
Discussion
Our results with SV40-lacZ mice indicate that in the nor-
mal bladder, a rich lymphatic vessel network is visible
from the adventitia through the detrusor smooth muscle.
It is characterized as a vascular network of blind ended,
thin-walled capillaries that merge to larger collecting
ducts, all positively stained with LYVE-1 antibody. In
sharp contrast with the dense blood vessel vascularization
of the bladder mucosa, we found that lymphatic vessels
are absent of the sub-urothelium being located much
Detail of the last frame of movie presented in Figure 14  (additional file 3) indicating the urinary bladder (red circle)  and tumor areas that are darker than the normal tissue  (waved green line delimit tumor areas) Figure 15
Detail of the last frame of movie presented in Figure 14 (additional 
file 3) indicating the urinary bladder (red circle) and tumor areas 
that are darker than the normal tissue (waved green line delimit 
tumor areas).
Double echo post-contrast MRI Figure 14
Double echo post-contrast MRI. This is a representative 
frame of a double echo MRI obtained in the same mouse bladder 
represented in Figure 13 after injection of Gd-Cy5.5. A movie is 
illustrated in additional file 3.
Double echo pre-contrast MRI Figure 13
Double echo pre-contrast MRI. This is a representative frame 
of a double echo MRI of 6-month old SV40-lacZ mouse bladder 
indicating the different scanning positions. A movie is illustrated in 
additional file 2.BMC Cancer 2007, 7:219 http://www.biomedcentral.com/1471-2407/7/219
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deeper in the lamina propria (Figures 6A, 6B, 7A, and 7B)
which seems to parallel the clinical findings in the human
bladder [35,36].
Our analysis indicates an increased lymphatic density dur-
ing cancer progression and a co-localization of Ki-67 with
some of LYVE-1-positive lymphatics, suggesting cancer-
induced lymphangiogenesis (Figure 4), as it was recently
suggested in human bladder cancer [10,37]. However, the
mechanisms for bladder lymphangiogenesis are not clear.
In contrast to blood vessel angiogenesis, the mechanisms
of lymphangiogenesis in general are still relatively vague
[38]. Vascular endothelial growth factor-C (VEGF-C) and
VEGF-D have been implicated as specific regulators of
lymphangiogenesis [39-43]. Both growth factors mediate
their biological activity mainly by VEGF receptor-3
(VEGFR-3, Flt-4) [44,45]. It remains to be determined
whether VEGF-C and VEGF-D along with VEGFR-3 play a
role in lymphangiogenesis during bladder cancer develop-
ment. Another interesting line of research involves LYVE-
1-positive tumor associated macrophages [46] that have
indeed been associated with tumor lymphangiogenesis
[47,48]. In the eye, a stepwise mechanism of inflamma-
tion-associated  de novo lymphangiogenesis involves
potential lymphatic progenitor cells [49] derived from cir-
culation that transmigrate through the connective tissue
stroma, presumably in the form of macrophages [49-51],
and finally incorporate into the growing lymphatic vessels
[52]. Our present findings indicate that in addition to
LYVE-1-positive lymphatic endothelial cells, during blad-
der cancer development, LYVE-1 positive macrophages
were found in the bladder detrusor muscle isolated from
SV40-lacZ mice. Although this may be only a circumstan-
tial finding, it opens a testable hypothesis on the role of
macrophages and other inflammatory cells in bladder
lymphangiogenesis. The introduction of SV40-lacZ along
with the visualization and quantification techniques
described here will permit further investigation on this
subject.
It has been proposed that lymphangiogenesis is correlated
with tumor metastasis. Increasing knowledge of the
tumor's biological significance in lymphatics within the
tumors (intratumoral lymphatics, ITLs) and at the tumor
periphery (peritumoral lymphatics, PTLs) has greatly pro-
moted understanding of tumor access into the lymphatic
system by inducing lymphangiogenesis or by co-opting
preexisting lymphatics [2]. Indeed, peritumoral lymphat-
ics have also been associated with both regional metasta-
sis and survival in bladder [37], lung [53], breast [54], and
prostate cancer [55]. But the question still remains as to
whether pre-existing vessels are sufficient to serve this
function, or whether tumor cell dissemination requires de
novo lymphatic formation or an increase in lymphatic size.
In this regard, Fernandez and collaborators reported that
in the human bladder, higher intratumoral LVD correlates
significantly with poor histological differentiation, and
that higher peritumoral LVD showed a significant associ-
ation with the presence of lymph node metastasis [10].
Although peritumoral lymphatic vessels contribute to
tumor metastasis, opposite views exist as to whether intra-
tumoral lymphatics have any role in tumor metastasis
[56,57]. Padera and collaborators examined functional
lymphatics associated with mouse tumors expressing nor-
mal or elevated levels of VEGF-C [58]. Although VEGF-C
over-expression increased lymphatic surface area in the
tumor margin and lymphatic metastasis, these tumors
contained no functional lymphatics, as assessed by four
independent functional assays and IHC staining [58].
These findings suggest that the functional lymphatics in
the tumor margin alone are sufficient for lymphatic
metastasis and should be targeted therapeutically [58].
Our MRI results are in agreement with those described by
Pandera and collaborators [58] in the sense that intratu-
mor lymphatic vessels have a reduced function when
compared to normal areas of the bladder.
Longitudinal studies of tumor size during the period of 2  months (n = 5) Figure 16
Longitudinal studies of tumor size during the period of 2 months 
(n = 5). Mean and SEM values for tumor volume, bladder volume, 
and fractional tumor volume obtained from five SV40-lacZ mice 
developing bladder tumor.
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MRI of mouse bladder using Gd-Cy5.5 as contrast agent Figure 17
MRI of mouse bladder using Gd-Cy5.5 as contrast agent. A. Gray-scale image of the bladder and tumors at pre-contrast before 
Gd-probe administration. B. Difference image obtained at 30 minutes post-Gd-probe contrast subtracted from the pre-contrast image. 
This image demonstrates an early enhancement by the contrast agent into the urinary bladder extravascular space, which may be attrib-
uted to vascular leakage. C. Difference image obtained at 80 minutes post-contrast subtracted from 30 minutes post-contrast. This image 
demonstrates a delayed enhancement due to drainage and pooling of the contrast agent, which may reflect uptake within the lymphatics 
in the bladder. D. Difference image obtained between images in B and C (80 min. post-contrast minus 30 min post-contrast, and the 30 
min. post-contrast minus the pre-contrast images). This image suggests that there is decreased drainage within tumorigenic areas, and 
perhaps a pronounced increase in uptake in the lymphatics within normal regions.
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Digital subtraction of the images between pre- and 80 minutes post-contrast Figure 18
Digital subtraction of the images between pre- and 80 minutes post-contrast. Images were acquired in two "phases" corre-
sponding to the biphasic kinetics of the BSA-Gd-DTPA [15]. The first or "early phase" comprised of images obtained just before i.v. 
administration of 200 μL Gd-Cy5.5 (dose of 500 mg/kg). Starting at 3 minutes post-injection, images were acquired every 7 minutes, up to 
2 hours post-contrast. The second block of MRI data was acquired up to 80 minutes after the first series of images. Images represents 
accumulation of Gd-Cy5.5 represented in three contiguous slices from the same bladder (positions -0.2 = A, -0.8 = B, and +0.8 = C). The 
red and yellow regions are active lymphatic vessels and consist of drainage events within the bladder interstitium.
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Another question answered by the present work was
whether an increase in the number of lymphatic vessels
leads to increased function. For this purpose, we followed
the strategy recently reviewed by Neeman and collabora-
tors [59]. The contrast agent introduced here was origi-
nally described by Dafni and collaborators [14-16], and
subsequently by Pathak and collaborators [15], for visual-
ization of lymphatics and determination of their function.
The modification of conjugating biotin-BSA-Gd-DTPA
[15] to Cy5.5 permitted us to use NIRF and MRI to follow
the dynamics of the same compound and calculate lym-
phatic vessel function. The advantage of using NIRF is the
faster time for data acquisition. NIRF information permit-
ted us to narrow the number of time points for subse-
quent MRI studies.
The proposed mechanism of visualization of BSA-Gd-
Cy5.5 (~82 kDa) is based on the presence of BSA which
prolongs its lifetime in circulation. Initially the probe is
confined to blood vessels and it is systemically distrib-
uted, and as the time passes it extravasates to the extracel-
lular space in points of increased vascular permeability.
Time-dependent clearance of the Gd-probe agent away from the bladder provides a strong indication of lymphatic vessel func- tion (LVF) Figure 19
Time-dependent clearance of the Gd-probe agent away from the bladder provides a strong indication of lymphatic vessel function (LVF). 
Figure 18 represents the comparison between tumor-bearing bladders (Figure A) and controls (Figures B and C). Data represents 
T1 values in [ms] with Bruker's MSMEVTR spin-echo method, including 3 slice packages chosen to include both normal and tumor regions 
in bladder. T1 values from these regions were normalized as percent of the reference site (muscle). In control bladders, two different 
normal regions were compared. This figure represents the time-dependent clearance of the contrast agent away from the bladder and 
provides a strong indication of LVF. Asterisks indicate a statistical significant difference (p < 0.05) between normal and tumor areas.
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Both NIRF and MRI are able to detect when BSA-Gd-cy5.5
starts to accumulate in the extracellular space and when its
accumulation reaches a plateau. This was done at the MRI
level by following the longitudinal relaxation rates (1/T1)
that correlates with increased uptake of the Gd-probe
from the blood vessels into the urinary bladder extra vas-
cular space. This phase was called the "early phase" in this
manuscript. After 80 minutes of the plateau, a second
series of MRI were started and followed the clearance of
BSA- Gd-Cy5.5 from the extravascular by the lymphatic
vessels. This was supported by ex vivo images which indi-
cated that, at this point, most of the BSA-Gd-Cy5.5 is
drained from the tissue by lymphatic vessels.
Although MRI lymphangiography does measure areas of
draining and pooling instead of directly evaluating lym-
phatic vessel function, the delayed enhancement observed
at later time points from the Gd-probe may also reflect
uptake of Gd-probe in the lymphatics. In addition, this
information can not be obtained any other way and clin-
ical studies attest the validity of using lymphangiography
for assessment of lymphatic vessel function [60-64]. A
step forward in this direction was introduced here by the
use of a single probe that can be imaged by MRI and NIRF.
The first indicates areas of draining and pooling and the
second permitted the temporal association of images with
cross-sections indicating the relative distribution of the
probe between CD31-positive blood vessels and LYVE-1-
positive lymphatic vessels.
As pointed out by Neeman and collaborators [59], con-
trast MRI data are typically dominated by vascular perme-
ability, which often masks the relatively slow lymphatic
drain. To separate vascular leakage from the lymphatic
drain, an avidin chase needs to be introduced [14,16]
which through the rapid clearance of intravenously
administered biotin-BSA-Gd-DTPA, allowed them to
experimentally track interstitial convection and lymphatic
drain in the absence of continuing vascular leakage
[14,16]. Our present MRI results are not corrected for vas-
cular leakage. Therefore, future experiments will take into
consideration this point for a more detailed analysis of
lymphatic vessel function using the advantage of the pres-
ence of biotin in the Gd-Cy5.5 molecule.
Another advantage of NIRF was to permit the collection of
tissues exhibiting fluorescence. In this regard, we were
able to further pursue the morphology of lymph sacs
using dextran-Cy5.5. This will allow us in the near future
to determine the contractility of lymph sacs and abdomi-
nal lymphatic vessels. The rhythmic activity observed in
the abdominal lymphatics draining the urinary bladder is
in agreement with recent results that indicated that
mesenteric lymphatic vessels have a true pacemaker
mechanism [65,66]. The experiment described in Figures
10, 11, 12 will permit the capture and evaluation of large
lymphatic function in health and disease.
Conclusion
The present work introduces a new double transgenic
mouse model that permits the visualization of lymphatic
vessels during bladder cancer progression, and introduces
new technologies for the visualization and quantification
of lymphatic vessel density and function by combining
NIRF and MRI imaging. The results presented here raise
the possibility of the study of lymphatic vessel activity in
vivo and in real time and raises the hypothesis regarding
the role of lymphangiogenesis during bladder cancer pro-
gression. It remains to be determined whether manipula-
tion of lymphatic vessel density and function would alter
bladder tumor progression.
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